Scout | Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)

This opportunity is no longer accepting applications.

grant

Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)

This grant opportunity aims to support the creation of a detailed plan for developing new treatments and preventive strategies for HIV and related health issues. It also helps in translating research into drug products suitable for submitting an Investigational New Drug (IND) application to the FDA.

Source

Agency: National Institutes of Health

Sub-agency: National Institute of Allergy and Infectious Diseases

Program: SBIR

Award

Award Ceiling: $225,000

Funding Amount: $225,000

Dates

Opportunity Released: August 14, 2023

Open for Submission: August 14, 2023

Submission Deadline: December 4, 2026

Application Window Closes: December 4, 2026

Keywords

HIV

next-generation treatments

HIV-associated comorbidities

coinfections

preventive strategies

product development

research translation

drug products

Investigational New Drug

FDA IND application.

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers